Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 11:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 240 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Intestinal Malabsorption Clear all
Completed Phase 2Phase 3 Interventional

Efficacy, Safety, and Tolerability Study of RP-G28 in Subjects With Lactose Intolerance

NCT02673749
View directory record Official record
Conditions
Lactose Intolerance
Interventions
RP-G28, Placebo
Drug · Other
Lead sponsor
Ritter Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 18, 2026, 11:58 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency

NCT02199496
View directory record Official record
Conditions
Gastrointestinal Inflammation Associated With CVID, CVID Enteropathy
Interventions
Stelara (ustekinumab)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Oct 18, 2026, 11:58 AM EDT
Completed Phase 2 Interventional Results available

PRV-015 in Gluten-free Diet Non-responsive Celiac Disease

NCT04424927
View directory record Official record
Conditions
Celiac Disease
Interventions
PRV-015, Placebo
Biological · Other
Lead sponsor
Provention Bio, a Sanofi Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
28
States / cities
Los Angeles, California • Ventura, California • Denver, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 18, 2026, 11:58 AM EDT
Enrolling by invitation Phase 4 Interventional

Evaluating RELiZORB Use for the Treatment of Feeding Intolerance in Adults With Moderate to Severe Acute Pancreatitis

NCT07583342
View directory record Official record
Conditions
Acute Pancreatitis (AP), Enhancing Enteral Nutrition Tolerance
Interventions
RELiZORB digestive enzyme (immobilized lipase) cartridge
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Bay Shore, New York • Manhasset, New York • Manhattan, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 18, 2026, 11:58 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Infant & Toddler Short Gut Feeding Outcomes Study

NCT01946503
View directory record Official record
Conditions
Short Bowel Syndrome, Intestinal Failure, Home Parenteral Nutrition
Interventions
Not listed
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
3 Months to 6 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 18, 2026, 11:58 AM EDT
Completed No phase listed Observational

Immune Response in Celiac Disease on In-vitro Gluten Challenge

NCT01909050
View directory record Official record
Conditions
Celiac Disease
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Oct 18, 2026, 11:58 AM EDT
Completed Phase 2 Interventional

Study of the Efficacy of Larazotide Acetate to Treat Celiac Disease

NCT00889473
View directory record Official record
Conditions
Celiac Disease
Interventions
Larazotide acetate, Placebo, Gluten 900 mg
Drug · Dietary Supplement
Lead sponsor
9 Meters Biopharma, Inc.
Industry
Eligibility
18 Years to 72 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
14
States / cities
Orange, California • Topeka, Kansas • Lexington, Kentucky + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 18, 2026, 11:58 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)

NCT00172185
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
teduglutide 0.05 mg/kg/d, teduglutide 0.10 mg/kg/d
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Omaha, Nebraska + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 18, 2026, 11:58 AM EDT
Enrolling by invitation No phase listed Observational

A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB

NCT05635747
View directory record Official record
Conditions
Short Bowel Syndrome, Malabsorption
Interventions
Relizorb Enzyme Cartridge
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 18 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 18, 2026, 11:58 AM EDT
Completed Phase 2 Interventional Results available

Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)

NCT05130047
View directory record Official record
Conditions
Chronic Diarrhea, Irritable Bowel Syndrome With Diarrhea, Bile Acid Malabsorption, Bile Acid Diarrhea, Bile Acid Malabsorption Syndrome Type II, Functional Diarrhea
Interventions
Aldafermin, Placebo
Drug
Lead sponsor
Michael Camilleri, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 18, 2026, 11:58 AM EDT
Completed Phase 1 Interventional

STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable Immunodeficiency

NCT00263237
View directory record Official record
Conditions
Common Variable Immunodeficiency
Interventions
STA-5326
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 18, 2026, 11:58 AM EDT
Completed No phase listed Observational

Retrospective Analysis of Treatment Outcomes in Patients With Bacterial Overgrowth Syndrome Diagnosed by D-Xylose Breath Testing

NCT01324895
View directory record Official record
Conditions
Small Intestinal Bacterial Overgrowth Syndrome (SIBO), Small Bowel Bacterial Overgrowth Syndrome (SBBOS)
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
Not listed
Enrollment
944 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 26, 2012 · Synced Oct 18, 2026, 11:58 AM EDT
Completed Phase 2 Interventional

Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac Disease

NCT00620451
View directory record Official record
Conditions
Celiac Disease
Interventions
larazotide acetate, placebo
Drug
Lead sponsor
9 Meters Biopharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Orange, California • San Francisco, California • Torrington, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 18, 2026, 11:58 AM EDT
Completed Phase 2 Interventional Results available

A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease

NCT06001177
View directory record Official record
Conditions
Celiac Disease, Coeliac Disease
Interventions
KAN-101, Placebo
Drug
Lead sponsor
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Colorado Springs, Colorado • Hialeah Gardens, Florida • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 18, 2026, 11:58 AM EDT
Completed Phase 3 Interventional

Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis

NCT00432861
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
PANCRECARB® (pancrelipase), Placebo
Drug
Lead sponsor
Digestive Care, Inc.
Industry
Eligibility
7 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 18, 2026, 11:58 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prognostic Indicators as Provided by the EPIC ClearView

NCT01476995
View directory record Official record
Conditions
Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation, Hypertension, Pyelonephritis, Acute Renal Failure, Renal Failure, Viral Hepatitis, Alcoholic Hepatitis, Steatohepatitis, Cirrhosis, Asthma, COPD, Bronchitis, Emphysema, Pneumonia, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Diverticulitis, Peptic Ulcer Disease, Irritable Bowel Syndrome, Cholecystitis, Pancreatitis, Malabsorption Disorders, Celiac Sprue, Diabetes
Interventions
Not listed
Lead sponsor
Epic Research & Diagnostics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Oct 18, 2026, 11:58 AM EDT
Completed Phase 2 Interventional Results available

Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury

NCT01845116
View directory record Official record
Conditions
Total Parenteral Nutrition-induced Cholestasis
Interventions
Omegaven®
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
4 Weeks to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 18, 2026, 11:58 AM EDT
Completed No phase listed Observational

Immune System and Gut Abnormalities in Patients With Common Variable Immunodeficiency With and Without Gastrointestinal Symptoms

NCT00015431
View directory record Official record
Conditions
Common Variable Immunodeficiency
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
10 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 18, 2026, 11:58 AM EDT
Completed No phase listed Observational

Adding Malabsorption for Failed Gastric Bypass

NCT01040481
View directory record Official record
Conditions
Clinically Severe Obesity, Obesity Recidivism, Inadequate Initial Weight Loss, Poor Weight Loss, Persistent Obesity, Refractory Obesity, Intractable Obesity
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Dec 29, 2009 · Synced Oct 18, 2026, 11:58 AM EDT
Not listed Phase 2 Interventional

Evaluation of the Efficacy and Safety of ALV003 in Symptomatic in Celiac Disease Patients

NCT01917630
View directory record Official record
Conditions
Celiac Disease
Interventions
ALV003, placebo
Drug
Lead sponsor
Alvine Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
79
States / cities
Decatur, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Oct 18, 2026, 11:58 AM EDT
Completed Not applicable Interventional

Gluten Sensor Device to Promote Gluten Free Diet Adherence and Quality of Life in Patients With Celiac Disease

NCT03321214
View directory record Official record
Conditions
Celiac Disease
Interventions
Gluten Sensor Dose-Finding Intervention
Other
Lead sponsor
Columbia University
Other
Eligibility
13 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 18, 2026, 11:58 AM EDT
Completed Not applicable Interventional

Teen and Young Adult Connections for Support From Multidisciplinary Professionals & Peers

NCT02987569
View directory record Official record
Conditions
Short Bowel Syndrome, Malabsorption, Malnutrition
Interventions
mConnect plus mobile connections to multidisciplinary professionals & peers, iPad use plus one mobile connections to multidisciplinary professionals & peers
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
13 Years to 30 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 18, 2026, 11:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of a Standard Meal on the Pharmacokinetic Profile of RP-G28 in Healthy Adult Male and Female Subjects

NCT03563846
View directory record Official record
Conditions
Lactose Intolerance
Interventions
RP-G28
Drug
Lead sponsor
Ritter Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 18, 2026, 11:58 AM EDT
Completed Phase 3 Interventional Results available

Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)

NCT00880100
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
Ultrase® MT12
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Years to 6 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
15
States / cities
Aurora, Colorado • Ann Arbor, Michigan • Grand Rapids, Michigan + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 18, 2026, 11:58 AM EDT